Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private PlacementGlobeNewsWire • 12/22/20
Is Cellectar Biosciences (CLRB) A Good Stock To Buy According To Hedge Funds?Insider Monkey • 11/27/20
Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/09/20
Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma PatientsGlobeNewsWire • 09/09/20
Cellectar Presents Poster at the AACR VIRTUAL MEETING: ADVANCES IN MALIGNANT LYMPHOMAGlobeNewsWire • 08/17/20
Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/10/20
Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual MeetingGlobeNewsWire • 07/21/20
Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug VehiclesGlobeNewsWire • 06/11/20
Cellectar Biosciences Announces Closing of $20 Million Underwritten Public OfferingGlobeNewsWire • 06/05/20
Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public OfferingGlobeNewsWire • 06/03/20
Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s MacroglobulinemiaGlobeNewsWire • 05/26/20
Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)GlobeNewsWire • 01/06/20
Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 StudyGlobeNewsWire • 12/16/19
Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology ConferenceGlobeNewsWire • 12/09/19
Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in BostonGlobeNewsWire • 10/17/19
Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) CongressGlobeNewsWire • 09/30/19